Updated on 7 September 2015
In a step to upgrade its pharmacovigilance services, Allergan Japan has announced that the company has implemented US-headquartered November Research Group's new software application, PRIMO Mobile.
PRIMO Mobile is a mobile data intake solution that enables field sales representatives, clinical research associates, and product vigilance teams in life sciences companies to quickly and easily capture and manage adverse events (AE) and product quality issues discovered during their mobile activities.
"We are very pleased that PRIMO Mobile has so readily met the diverse needs of our customer Allergan Japan," said Brad Gallien, Vice President of Product Development at November Research Group. "With such a diverse portfolio of products, Allergan's Medical Representatives faced a difficult task of reporting AE and PC information they discovered while in the field. With PRIMO Mobile, they can now comply with their regulatory reporting requirements in just a few gestures on their tablet or phone."
PRIMO Mobile is designed to replace the paper and fax based AE data collection practice that many companies currently use. It allows company representatives in the field to quickly create a report on their tablets or smartphones, and send the report back to the safety team for further review. By directly connecting the safety team with field personnel, PRIMO Mobile helps streamline the initial report intake and follow-up process.
PRIMO Mobile is a modern and smart application that also includes several handy tools to allow users to record narratives, scan paper documents, and track locations. These electronic capture features increase the quality of the AE data from the beginning of the intake process.
PRIMO Mobile is the latest addition to the PRIMO family by November Research Group. It is designed to provide a solution that helps life science companies expedite the capture of adverse events, facilitate the pharmacovigilance workflow, and ensure the safety team is in compliance with regulatory requirements.